• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
RedNeT Presentation
 

RedNeT Presentation

on

  • 2,413 views

Presentation from Dr Ornella Corazza and Zoe Davey about the RedNeT project; an ICT prevention service addressing the use of novel compounds in vulnerable individuals

Presentation from Dr Ornella Corazza and Zoe Davey about the RedNeT project; an ICT prevention service addressing the use of novel compounds in vulnerable individuals

Statistics

Views

Total Views
2,413
Views on SlideShare
2,395
Embed Views
18

Actions

Likes
1
Downloads
25
Comments
0

2 Embeds 18

http://www.slideshare.net 16
http://www.drugeducationforum.com 2

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    RedNeT Presentation RedNeT Presentation Presentation Transcript

    • + Recreational Drugs European Network: an ICT prevention service addressing the use of novel compounds in vulnerable individuals Zoe Davey Dr Ornella Corazza ReDNet Project ReDNet Project Institute of Psychiatry, King’s College London School of Pharmacy, University of Hertfordshire zoedavey@kcl.ac.uk o.corazza@herts.ac.uk Drug Education Forum AGM, London, UK 4th March 2010
    • + Overview of the ReDNet Project Dr Ornella Corazza University of Hertfordshire o.corazza@herts.ac.uk
    • + ReDNet Project Initial Situation: Problem Analysis   Hundreds of websites dedicated to the dissemination of new drugs and provide detailed ‘recipes’ for synthesizing, growing, and consuming a variety   These drugs are constantly appearing in more sophisticated forms   Lack of scientific knowledge   Can remain unregulated for a long period of time   Often sold as ‘something’ else   Young people targeted   Attractive messages, accessible   New products alerts via SMS, email, etc
    • + ReDNet Project Initial Situation: Problem Analysis In the last decade there has been a dramatic change in the social context of substance misuse, which has shown rapid and unexpected developments. Not only have the types of recreational drugs changed, but also the modalities of intake, and the places where they are purchased and consumed (Gordon et al., 2006; Schepis et al., 2008; Schifano et al., 2006; Corazza et al 2009).
    • + ReDNet Project Aims   To develop an integrated ICT prevention approach focused on novel synthetic and herbal compounds and combinations, targeted at young and vulnerable individuals.   To investigate the potential of ICT tools in drug prevention approaches focusing on novel psychoactive compounds
    • + ReDNet Project Working Hypothesis   Traditional forms of intervention appear to be negatively appraised by those ‘at risk’:   Fear based and moralistic   Theoretical and didactic   Focused on traditional drugs (which are not the only interest of young people)
    • + ReDNet Project Objectives   To develop specific, balanced, non judgmental prevention/ harm minimisation messages   To pilot a number of ICT tools that are informed by available literature, accurate and up-to-date information on novel psychoactive compounds, and input from the target group(s)   To assess the feasibility of a variety of the implemented ICT tools /prevention approaches
    • + ReDNet Project   Target Groups   Young people (16-24) who don’t have access to appropriate drug information and/or treatment services (the online community, high school students, university students etc)   Health and other professionals working directly with the above group who are often no up-to-date with information about new drugs and novel compounds   Methods   To develop and pilot a number of approaches using different ICT tools e.g., SMS, Social networking (Facebook/Twitter), Multimedia ( YouTube), Smartphone applications (iPhone), Virtual worlds (Secondlife)   Involve target groups(s) in the development of appropriate content (taking into account possible iatrogenic effects)   Use the Psychonaut Web Mapping system as a source of information on new drugs and emerging trends (continue to update this resource)
    • + ReDNet Project   Expected outcomes   Raise awareness of novel compounds and the potential harms associated with their use   To have contributed to the development of the first ICT prevention model of its kind that is functional at the European level   To have developed a model for effectively targeting young people, making them more aware of the health risks associated with the use of ‘legal highs’ which are perceived as ‘safe’ by a number of users   To enhance scientific knowledge and understanding of novel recreational drugs amongst relevant professionals   To have piloted and assessed the risk associated with the dissemination of information on novel compounds to young people
    • + ReDNet Project ReDNet Research Group Project Details University of Herfordshire, UK 24 months (start date April 2010) Institute of Psychiatry, King’s College Funded by the EU Executive Agency for London, UK Health and Consumers in the framework of Institute of Psychiatry and Neurology, the Public Health Programme [2009 12 26] Poland Main Beneficiary: Bergen Clinics Foundation, Norway Professor Fabrizio Schifano De Sleutel, Belgium University of Hertfordshire College Lane Servizio Salute Regione Marche, Italy Hatfield Consorci Mar Parc de Salut, Spain Hertfordshire UK LVR, University of Duisberg-Essen, Germany f.schifano@herts.ac.uk National Institute for Drug Prevention, Hungary DrugScope UK
    • + Drugs on the Internet Dr Ornella Corazza School of Pharmacy University of Hertfordshire o.corazza@herts.ac.uk
    • + Drugs on the Internet Examples from the Psychonaut Web Mapping Project 2008-2009   412 compounds   Technical Reports   Salvia divinorum   Phalaris Arundinacea   Spice   Ephedra   Mephedrone   Kola Nut   Bromo-dragonfly   Benzydamine (Tantum Rosa)   Lyrica (Pregabalin)   HU-210   Sassafras   Sinicuichi   Wild Dagga   GBL, GHB, 1,4-BDO   Gotu Kola   2CB   Jurema   Peyote   Happy Caps   MDPV   Norspan   5-MeO-AET   Herkinorin   JWH-018   Minikikke/Superkikke   JWH-073   4-AcO-MET   Ikathazo   Syrian Rue   Papaver somniferum   5-MeO-MiPT
    • + Psychonaut Web Mapping Project Technical Report
    • + Psychonaut Web Mapping Project Example
    • + Psychonaut Web Mapping Project Example
    • + Psychonaut Web Mapping Project Example
    • + Lyrica (Pregabalin)
    • + Lyrica (Pregabalin)
    • + Prescription drugs and other   Darvon   Prozac   Lyrica   Ritalin   Viagra   Anabolic Steroids   Barbiturates
    • + Online buyers often can   Contact sellers directly   Get alerts about new products advertised by the seller via text messages, or instant messages   Email product to a friend
    • + Second Life
    • + Emerging trends Further results of the Psychonaut Web Mapping Project Zoe Davey Institute of Psychiatry King’s College London zoe.davey@kcl.ac.uk
    • + Beta-ketones   Synthetic stimulant compounds sharing psychoactive properties of cocaine, MDMA (ecstasy), and/or amphetamines   Sold as ‘research chemicals’ as well as commercially as ‘plant feeder’, ‘bath salts’, ‘multivitamins’ and/or ‘not for human consumption’   Examples include   Mephedrone – structurally similar to methcathinone (beta-ketone analogue of methamphetamine)   Methedrone (bk-PMMA) – beta-ketone analogue of PMMA (structurally similar to PMA)   Methylone (bk-MDMA) – beta-ketone analogue of MDMA   Flephedrone (4-FMC) – analogue of methcathinone   Butylone (bk-MBDB) – beta-ketone analogue of MBDB (close analogue of MDMA)   Ethylone (bk-MDEA) – beta-ketone analogue of MDEA (close analogue of MDMA)   Buphedrone – analogue of methcathinone   Ethcathinone – analogue of methcathinone
    • + Mephedrone Miaow, 4-MMC, MMCat, Meph, Bubbles, Drone, Rush etc.   4-methylmethcathinone   (Semi-)synthetic compound related to cathinone (identified in khat)   Appeared online in or around 2007   Popularity in Sweden and Denmark in 2008   Accelerated rise in popularity in 2009 (especially in the UK)   Increased media attention, fatalities and non-fatal overdoses   Compared variously to amphetamine, MDMA (ecstasy), and cocaine – has stimulant, empathogenic/entactogenic, and hallucinogenic properties   Controlled in: Australia, Denmark, Estonia, Finland, Germany, Israel, Norway, Romania, Sweden
    • + Mephedrone ‘Plant feeder’, ‘Bath Salts’, ‘Multivitamins’, and/or ‘Not for human consumption’ ‘Intended to promote speedy growth in all plants without compromising quality. Guidance: Large shrubs use 1 feeder each, smaller shrubs and shoots use half a feeder. It is not recommended that you use more   Widely available to purchase online than 2 feeders in a single day as this   “buy mephedrone”  105,000 hits in Google could have adverse effects on your plants. NOT FOR HUMAN CONSUMPTION’   Marketed online and via social networking site (Facebook, Twitter, YouTube) ‘Relax and soak away Concentrated bath salts, only use as advised,   Commonly sold as powders or in capsules PLEASE do not use this as SNUFF!!! Add the contents to a hot bath to   Sold as not for human consumption to avoid naturally soften the water which will leave you feeling very soothed and existing legislation such as the Medicines act relaxed. This is used to mimic the natural hot springs of the greek sea.   Purchase price: NOT FOR HUMAN CONSUMPTION’   £10 for 2 capsules (250-300mg capsules)   £10-15 for 1g powder
    • +   ~40% of UK respondents to the 2009/2010 MixMag Drug Survey had tried the drug   Most commonly administered orally (bombing, gums, dissolved), intranasally (snorting)   Dose usually varies between 100mg – 1g, but can be upwards of 4g (incl. redose)   Reportedly taken in combination with a variety of other compounds, including:   Alcohol   Other research chemicals   Cocaine   MDMA   Ketamine (‘Challenge’)   Heroin (similar to ‘speedball’   Cannabis, Kratom, depressants (during comedown period)
    • + Mephedrone Stimulant, empathogenic, and hallucinogenic effects Desired psychoactive effects Side effects   Euphoria   Anorexia   Empathy   Nausea   Sociability   Respiratory difficulties   Stimulation   Muscular clenching   Intensification of sensory   Ulcerations stimulation   Amnesia   Mild sexual stimulation   Dermatitis like symptoms   Mood enhancement   Discolouration of the joints   Hallucinations   Anxiety   Similar to cocaine, MDMA, and   Depression Amphetamine
    • + Mephedrone Pharmacology and toxicology   Little is known about the pharmacology and toxicology of mephedrone in humans   Limited to case studies, short reports, and focus groups   According to users there is an addictive quality to the substance   Binges and redosing in a single session common   Reported development of tolerance   Five reported fatalities in which mephedrone has been implicated   Denmark, May 2008   Sweden, December 2008   UK, November 2009 (14 year-old, female)   UK, January 2010 (18 year-old, male)   UK January 2010 (49 year-old female)   Reported non-fatal overdoses in the UK
    • + Contact For further information about the ReDNet Project or the Psychonaut Web Mapping Project www.psychonautproject.eu Dr Ornella Corazza o.corazza@kcl.ac.uk Zoe Davey zoe.davey@kcl.ac.uk info@psychonautproject.eu